NVIDIA reports that pharmaceutical giant Eli Lilly has unveiled the pharmaceutical industry's largest and most advanced in-house AI facility. This cutting-edge facility is built on the world's inaugural NVIDIA DGX SuperPOD architecture, which is outfitted with DGX B300 systems. It boasts an integration of over 1,000 B300 GPUs, facilitating seamless and efficient full-system communication via a unified high-speed network framework.

As a cornerstone infrastructure, this AI facility will underpin the entire AI lifecycle management, encompassing data intake, model training, and high-throughput inference. This will empower Eli Lilly to make significant strides in pivotal domains like molecular discovery and drastically reduce the timeframes for drug development. Furthermore, Eli Lilly intends to grant access to some of its proprietary AI models to early-stage biotech firms through the TuneLab platform, thereby nurturing an open and cooperative R&D ecosystem.